CIK 0001590877 · Non-accelerated filer<br>Smaller reporting company
REGENXBIO Inc.
Sign in to watch- Ticker
- RGNX
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 471851754
- Phone
- 240-552-8181
- Business address
- 9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD, 20850
- Former names
- ReGenX Biosciences, LLC
- Open-market buys, last 90 days
- $949,381
- in 1 filing
- Open-market sales, last 90 days
- $0
- in 0 filings
Net +$949,381. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-11-01 | Malzahn Craig Chief Technology Officer | Grant or award | +27,777 | 109,737 | ||
| 2026-11-01 | Chan Mitchell Chief Financial Officer | Grant or award | +24,305 | 147,120 | ||
| 2026-11-01 | PAKOLA STEVE Chief Medical Officer | Grant or award | +34,722 | 240,263 | ||
| 2026-11-01 | Christmas Patrick J. Chief Strategy & Legal Officer | Grant or award | +34,722 | 240,690 | ||
| 2026-09-01 | Malzahn Craig Chief Technology Officer | Shares withheld for taxes | −234 | $9.32 | $2K | 81,960 |
| 2026-09-01 | Chan Mitchell Chief Financial Officer | Shares withheld for taxes | −4,902 | $9.32 | $46K | 122,815 |
| 2026-08-27 | Ciongoli Gregory Austin Director | Purchase | +53,407 | $9.36 | $500K | 118,035 |
| 2026-08-26 | Ciongoli Gregory Austin Director | Purchase | +49,196 | $9.14 | $450K | 64,628 |
| 2026-08-25 | Ciongoli Gregory Austin Director | Grant or award | +15,432 | 15,432 | ||
| 2026-08-25 | Ciongoli Gregory Austin Director | Grant or award · Stock Options (Right to buy) | +69,609 | 69,609 | ||
| 2026-08-01 | PAKOLA STEVE Chief Medical Officer | Shares withheld for taxes | −7,468 | $9.69 | $72K | 205,541 |
| 2026-08-01 | Christmas Patrick J. Chief Strategy & Legal Officer | Shares withheld for taxes | −4,699 | $9.69 | $46K | 205,968 |
| 2026-07-02 | PAKOLA STEVE Chief Medical Officer | Option exercise 10b5-1 | +2,161 | $7.86 | $17K | 215,170 |
| 2026-07-02 | PAKOLA STEVE Chief Medical Officer | Sale 10b5-1 | −2,161 | $13.64 | $29K | 213,009 |
| 2026-07-02 | PAKOLA STEVE Chief Medical Officer | Option exercise · Stock Options (Right to Buy) 10b5-1 | −2,161 | 64,812 | ||
| 2026-07-01 | Simpson Curran Chief Executive Officer | Shares withheld for taxes | −6,818 | $13.09 | $89K | 338,053 |
| 2026-07-01 | PAKOLA STEVE Chief Medical Officer | Option exercise | +36,725 | $7.86 | $289K | 249,734 |
| 2026-07-01 | PAKOLA STEVE Chief Medical Officer | Sale | −36,725 | $12.86 | $472K | 213,009 |
| 2026-07-01 | PAKOLA STEVE Chief Medical Officer | Option exercise · Stock Options (Right to Buy) | −36,725 | 66,973 | ||
| 2026-06-30 | Simpson Curran Chief Executive Officer | Grant or award | +1,453 | $10.18 | $15K | 344,871 |
Page 1 of 11 · 216 trades